Agenda

Overview | Mission
Green sustainability
Social responsibility
Governance
Sartorius at a glance

- ~€3.4bn Sales revenue 2023
- ~15% Sales CAGR\(^1\) 2013-2023
- 28.3% EBITDA margin\(^2\) 2022
- 60+ Locations worldwide, HQ in Göttingen, Germany
- ~14,600 Employees 12/2023

Two divisions with clear focus on attractive biopharma and life science industry

1 In constant currencies 2 Excluding extraordinary items
Supporting customers from drug discovery to commercial-scale production of biologics

Bioprocess Solutions Division

Molecule development
Cell line and process development
Upstream & downstream production

Quality | Testing | Validation

Lab Products & Services Division
Long-term value creation by focusing on four material topics

1. Economic performance
   - Advance innovation, contribute to medical progress

2. Ecologic performance
   - Protect the environment by reducing emissions, waste and water use
   - Assuming responsibility for our products throughout their life cycles

3. Social performance
   - Find and retain employees, provide good working conditions
   - Protect health and safety, promote continuous development

4. Governance performance
   - Responsible corporate governance and compliance
   - Respect for human rights throughout the supply chain
At the core of our business: “Good health and well-being”

Our mission

We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine.
Health is one of the most relevant global topics

Growing and aging population

World population over 65 years\(^1\)

\(~1.6\text{bn}\)

\(~0.8\text{bn}\)

2022 2050

1 United Nations: World Population Prospects, 2022

Development and manufacturing of drugs are time-consuming and costly\(^2\)

Research > Commercial production

>\(€2\text{bn}\)

1 out of 10,000

> of 10 years

2 Based on data from the Tufts Center for the Study of Drug Development and the Association of the British Pharmaceutical Industry
The challenge: Many innovative biotech medications are very expensive

**Rheumatism**
- Monoclonal antibody therapy
- \(~€12,000\) Annual cost of treatment in Germany

**Blood cancer**
- CAR-T cell therapy
- \(~€280,000\) Cost per treatment in Europe

**Hemophilia**
- Gene therapy
- \(~€3.5\ mn\) Cost per treatment in the USA
Three drivers for innovation: The key to achieve ESG targets

**Product development**
in areas of own core competencies

**Acquisitions**
of complementary and differentiating technologies

**Cooperations**
with partners that are leading in areas of future relevance

- **Bioanalytics**
- **Downstream processing**
- **Cell and gene therapies**

- **Advanced materials**
- **3D cell printing technology**
- **Process automation & digitization**
- **Bioanalytics**

Product launch:
Sartobind® Rapid A
Sartorius’ technologies enable researchers to achieve results faster, ...

Example: digitalization and automation of laboratory processes

- More experiments with lower error rate
- Data and analysis for better decisions
- Shortening time-to-clinic

Saves more than 5 weeks in the selection of cell clones
... to increase yield and efficiency in biopharma production ...

Example: new, innovative bioprocess technologies

CIMmultus®

Downstream processing time reduced by 60%
Significantly higher yields of viral vectors required for gene therapies

Sartobind® Rapid A

20x Higher productivity compared to classical column chromatography
>30% Cost reduction in clinical manufacturing
A strong lever of impact on green aspects: Our customers’ operations

- Global GHG emissions in CO₂ equivalents in 2021¹
  - >50 billion tons

- Of these related to the healthcare sector²
  - ~4-5%

- Attributable emissions of Sartorius³ make up
  - ~0.025%

¹ UN Environment Programme „Emissions Gap Report 2022“, preliminary estimate ² According to World Economic Forum June 2021 ³ Own calculations
SU technologies help to reduce water and energy consumption at the customers’ sites

Water consumption\(^1\) ~ -30%

Energy consumption\(^1\) ~ -30%

1 Based on data from Flanagan et al (2011). LCA of a mAb process at 2,000 L scale.
Process intensification leads to higher efficiency and less eco impact

Process Mass Intensification\(^1\) = \(-50\%\)

PMI = \[
\frac{\text{Total raw materials, consumables and water (kg)}}{\text{Product (kg)}}
\]

1 Data from in-house case study: 300 kg/year and 1,500 kg/year throughputs. PMI measured for a traditional stainless steel fed batch process (SS 15kL), and a process intensification scenario (SU dynamic perfusion process with downstream multi-column chromatography). Data was generated using BioSolve modeling software.
Data analytics solutions support customers in further CO₂ reduction

Success Story
Implementation of Umetrics® Suite data analytics tools at Michigan University helps increase process efficiency and reduces carbon footprint significantly

Phase 1 | prevented
780 tons CO₂e

Phase 2 | aims to prevent
10,000 tons CO₂e
Agenda

Overview | Mission
Green sustainability
Social responsibility
Governance
Sartorius' environmental fields of action at its own operations
Only a small portion of emissions under own control

<table>
<thead>
<tr>
<th>Scope</th>
<th>Description</th>
<th>Percentage of total emissions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scope 1</strong></td>
<td>Direct emissions from sources for which we are responsible, such as our manufacturing processes or company vehicles.</td>
<td>~10%</td>
</tr>
<tr>
<td><strong>Scope 2</strong></td>
<td>Indirect emissions from purchased electricity, steam, heating and cooling at our 60+ sites worldwide.</td>
<td>~10%</td>
</tr>
<tr>
<td><strong>Scope 3</strong></td>
<td>Indirect emissions from sources upstream and downstream in the value chain that we only partially control, e.g. purchased goods/services, product life cycle, employee commuting.</td>
<td>~90%</td>
</tr>
</tbody>
</table>
Ambitious mid- and long-term climate targets

2030 mid-term targets

- ~10% p.a. on average reduction of CO₂eq emission intensity
- Zero avoidable* emissions in Scopes 1 and 2
- 100% electricity from renewable sources

Sartorius commits to extending its climate ambition by targets approved by the Science Based Targets initiative.

2045 long-term target

Net-zero emissions

Decarbonization of the entire supply chain in collaboration with suppliers and customers

*Process emissions from membrane manufacturing are currently considered unavoidable based on available technology.
Additional sustainability target: Climate neutral by 2045

Long-term target complements existing climate strategy

- Decarbonization in collaboration with suppliers and customers
- 100% electricity from renewable sources by 2030
- Electricity from hydropower at German sites in Göttingen, Guxhagen and Ulm since 2021

Sartorius commits to extending its medium-term climate related ambition by targets approved by the Science Based Targets initiative.
### CO₂ reduction levers across the value chain

<table>
<thead>
<tr>
<th>Upstream (Scope 3)</th>
<th>Production Scope 1&amp;2</th>
<th>Downstream (Scope 3)</th>
<th>Other (capital goods, employee commuting, buildings)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purchased goods &amp; services</td>
<td>Eco-design products &amp; packaging</td>
<td>Eco-design products &amp; packaging</td>
<td>Buildings &amp; construction</td>
</tr>
<tr>
<td>Efficiency in manufacturing</td>
<td>Efficiency in manufacturing</td>
<td>Efficiency in manufacturing</td>
<td>Capital goods</td>
</tr>
<tr>
<td>Supplier engagement</td>
<td>Eco-design packaging</td>
<td>Procure renewable energy</td>
<td>Commute sustainably</td>
</tr>
</tbody>
</table>

#### Upstream (Scope 3)
- Purchased goods & services
- Eco-design products & packaging
- Efficiency in manufacturing
- Supplier engagement

#### Upstream incl. int. transportation
- Eco-design packaging
- Transport
  - Frequency
  - Distance
  - Fright mode
  - Fuels
- Production process steps

#### Business travel
- Reduce travel
- Sustainable travel

#### Manufacturing & warehousing
- Manufacture
- Improve energy efficiency
- Produce clean energy
- Procure renewable energy

#### Downstream (Scope 3)
- Eco-design packaging
- Transport
  - Frequency
  - Distance
  - Fright mode
  - Fuels
- Process intensification

#### Product use & end of life
- Eco-design products & packaging

#### Other
- Buildings & construction
- Capital goods
- Commute sustainably
Expanding renewable energy capacity at Sartorius’ sites worldwide

North America

- Yauco, PR
  - In % of group: ~14
  - Renewable energy %: <0.5
  - Outlook: >90% in 2030

- Aubagne, FR
  - In % of group: ~5
  - Renewable energy %: ~94
  - Outlook: 100% in 2025

- Royston, Stonehouse, UK
  - In % of group: ~3
  - Renewable energy %: 0
  - Outlook: >90% in 2027

North America

- Helsinki, Kajaani FI
  - In % of group: ~4
  - Renewable energy %: ~52
  - Outlook: 100% in 2030

- Banglore, IN
  - In % of group: ~2
  - Renewable energy %: ~10
  - Outlook: >60% in 2023

- M’hamdia, TN
  - In % of group: ~3
  - Renewable energy %: 0
  - Outlook: 100% in 2030

- Göttingen, DE
  - In % of group: ~49
  - Renewable energy %: ~45
  - Outlook: 100% in 2030

Expansion of renewable energy capacity depending on availability of renewable energy sources

* FY 2022
Flexsafe®- first film designed for recycling

A milestone on the way to circularity

- From 20ml to 2,000l, Flexsafe® is the first film in the industry designed for recycling in a standard polyethylene waste stream
- Used in bioprocessing for non-hazardous applications, it can technically be recycled into raw materials with quality equivalent to pristine grades of polymers.

Partners

![Partners Logos]
Materials and circularity: Transitioning towards a circular economy

Our ambitions

We aim to optimize the selection and use of materials to improve our products’ environmental footprint.

- Optimize use of resources
- Avoid packaging waste
- Recycle production waste
- Life cycle analysis

2030 Circularity targets

>75%
Sales revenue with products designed according to circularity principles

Zero
operational waste to landfill

1 including product and transport packaging
Circular economy: New, medium-term goals defined

Decoupling economic growth and environmental pollution

- >75% of sales revenue with products designed according to circularity principles¹
  - Durability
  - Lifespan
  - Reusability
  - Repairability
  - Demontage
  - Recyclability
  - Ability to return to biological cycle
  - Other cycle-oriented optimization of the use of the product or material

- Zero operational waste to landfill

¹ including product and transport packaging
Current projects regarding the single-use technology life cycle

<table>
<thead>
<tr>
<th>Feedstock</th>
<th>Beginning of life</th>
<th>Production</th>
<th>Product usage</th>
<th>Product end of life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fossil</td>
<td>Naphtha Cracker</td>
<td>Resins</td>
<td>Product</td>
<td>Scrap</td>
</tr>
<tr>
<td></td>
<td></td>
<td>→</td>
<td>→</td>
<td>PMI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>→</td>
<td>→</td>
<td>Recycling Options</td>
</tr>
</tbody>
</table>

1. Alternative Feedstock
2. Less Material
3. Scrap Reduction Recycling Program
4. PMI
5. Recycling Options
Initiatives to improve waste management in Aubagne

Enhanced film recyclability

Reduced film consumption

Improved waste collection and sorting

Increased waste recycling

Total Waste (t/1000 Units)

2018: 0.97  2019: 0.89  2020: 0.63  2021: 0.52

Waste Processing

2018: 17% Landfill  26% Energy Recovery  57% Waste Recycling  12% Recycling
2019: 15% Landfill  19% Energy Recovery  66% Waste Recycling  4% Recycling
2020: 12% Landfill  4% Energy Recovery  84% Waste Recycling  4% Recycling
2021: 10% Landfill  6% Energy Recovery  84% Waste Recycling  4% Recycling

1 Figure taken from: Vachette, Elisabeth & Fenge, Christel & Cappia, Jean Marc & Delaunay, Lucie & Greller, Gerhard & Barbaroux, Magali. (2014). Robust and convenient single-use processing: The superior strength and flexibility of flexsafe bags. 12.
Water and wastewater: Improve water efficiency in own operations

The ambitions

- Reduce use of drinking water, increase use of rainwater
- Decrease wastewater, increase water recycling
- Optimization of production cycles with solvents

Water is primarily used in BPS for membrane production and modification
Solvent and water reuse at the Yauco plant

4 distillation columns
Processing capacity: 16,500 kg/day of spent solvent (oldware)

3.9 million kg of oldware processed for reuse
11.9 million litres of water processed for reuse

90% recovery of 2-pyrrolidone (2P) from oldware
98% recovery of Isopropanol (IPA) from oldware

Base April 2022
Supply chain due diligence act: Risk assessment

**Hard facts risk assessment**
- Country risks
- 3rd party assessment
- Code of Conduct
- Certificates

**Soft facts risk assessment**
- Sustainability report/strategy
- Commitment to SDGs
- Member Sustainability Association

**Actions with supplier**
- Improvement actions

If high risk

> 90%1
> 50%1
> 40%1

1 Coverage in terms of spend as of June 2023
Agenda

Overview | Mission

Green sustainability

Social responsibility

Governance
Strong increase in personnel over 5 years: 62% more employees

After strong team growth, current focus on efficiency

Many opportunities to grow with the company

Less than 2 years in the company: 55%

69% of management positions filled internally

~1,400 new jobs per year

<table>
<thead>
<tr>
<th>Year</th>
<th>Employees</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>9,036</td>
</tr>
<tr>
<td>2020</td>
<td>10,637</td>
</tr>
<tr>
<td>2021</td>
<td>13,832</td>
</tr>
<tr>
<td>2022</td>
<td>15,942</td>
</tr>
<tr>
<td>2023</td>
<td>14,614</td>
</tr>
</tbody>
</table>
An increasingly diverse team that brings in a variety of perspectives

**International workforce**
- 113 Nationalities
- 70% Non-German managers

**Balanced age structure**
- ≤29 years: 16%
- 30-39 years: 38%
- 40-49 years: 24%
- ≥50 years: 22%

**Share of women at a high level**
- 39% Share of women in the entire workforce
- 33% Share of women at 1st and 2nd management levels
- 41% Female executives on 1st level below the Board

**Goal 2025**

1/3
High employee satisfaction reflected internally and externally

87% are proud to work for Sartorius
77% say they contribute to the company’s mission
82% agree that Sartorius respects and strengthens diversity

3.6 ★★★☆☆
glassdoor
Intern. competitors Ø 3.7

4.0 ★★★★★
 kununu
DAX40 Ø 3.8

As of Q1 2024
Promoting science, education and innovation – also beyond our walls

Cell Culture Facility at Penn State | Supporting groundbreaking research with $1.5 million

Life Science Factory | Promoting startups and attract entrepreneurs in life sciences

LifeScienceXplained | Creating a stage for science communicators since 2021
Engaged in humanitarian aid and disaster relief globally

**action medeor** provides medical care to humanitarian organizations and health centers all over the world.

Our latest commitments include

- Support for earthquake victims of in Türkiye and Syria
- Humanitarian aid for the people of Ukraine
- Healthcare support in Guatemala
- Pharmaceutical training in West Africa
Agenda

Overview | Mission

Green sustainability

Social responsibility

Governance
Sartorius actively manages its sustainability impacts, risks and opportunities at its own operations

Existing and upcoming EU regulation

Corporate Sustainability Due Diligence Directive (CSDDD)

Taxonomy Regulation

Corporate Sustainability Reporting Directive (CSRD)

Annual management process

1. Identify relevant topics
2. Assess material IRO
3. Define measures / action plan
4. Monitoring
5. Reporting
6. Policy review
Multiple data points to be consistently tracked consistently

<table>
<thead>
<tr>
<th>Reporting topics</th>
<th>Challenges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Climate</td>
<td>&gt; 80 disclosure requirements</td>
</tr>
<tr>
<td>Water</td>
<td>&gt; 1,000 data points</td>
</tr>
<tr>
<td>Pollution</td>
<td>17 GHG emission categories</td>
</tr>
<tr>
<td>Resources</td>
<td>Data from multiple sources</td>
</tr>
<tr>
<td>Workers in the value chain</td>
<td>Concepts for data calculation and estimates</td>
</tr>
<tr>
<td>Consumers</td>
<td>Data governance and enrichment projects</td>
</tr>
<tr>
<td></td>
<td>Continuous data improvement</td>
</tr>
</tbody>
</table>

Reporting partially based on external data which can be subject to changes and specifications; therefore, continuous and retrospective restatements of certain data might be necessary.
Alignment of 2023 turnover & expenditures with EU taxonomy

Total sales revenues in %:
- Not Taxonomy-eligible: 61%
- Taxonomy-eligible but not aligned: 39%
- Taxonomy-aligned: 0%

Total CapEx in %:
- Not Taxonomy-eligible: 73%
- Taxonomy-eligible but not aligned: 22%
- Taxonomy-aligned: 5%

Total OpEx in %:
- Not Taxonomy-eligible: 40%
- Taxonomy-eligible but not aligned: 58%
- Taxonomy-aligned: 2%

All figures rounded

1 Sartorius does not have any taxonomy-eligible economic activities for which it would currently have been possible to assess compliance with the technical screening criteria as legislation only addresses particularly relevant economic activities for the achievement of the environmental objectives in the field of climate change mitigation and climate change adaptation, i.e. only a limited range of industries is covered.
Sartorius Group

Sustainability ratings and partnerships

Listed in

DAX 50 ESG

Sustainability ratings

MSCI AA
ecovadis Silver
SUSTAINLYTICS Low risk
CDP C

Memberships and cooperation in internationally renowned initiatives and platforms

Sustainable Development Goals
Global Compact
SAP

EcoSense
Ecovadis

Next Integrity
Prewave

BPSA
DFKI
NIMBL
BioPhorum

Actionmedeor
FBA
Charta der Vielfalt
Sartorius legal structure

Sartorius AG (~69.0m shares)
Stock market listed in Germany

Ordinary shares (~34.2m shares)
- ~55% Administered by executor
- ~38% Bio-Rad Laboratories
- ~7% Free float

Preference shares (~34.8m shares)
- ~72% Free float
- ~28% Bio-Rad Laboratories

97.3m shares
- ~71.5% Sartorius AG
- ~28.5% Free float

Sartorius Stedim Biotech S.A.
Stock market listed in France

~71.5%

100%

Other Sartorius subsidiaries

Bioprocess Solutions division

Lab Products & Services division

Sartorius Group operational setup

1 The ownership relates to outstanding shares and thus excludes treasury shares. Information on shareholdings and shares in free float pursuant to the disclosure requirements of Sections 33 et seq. of the German Securities Trading Act (WpHG) and the shareholders’ own disclosures. The legal disclosure requirements refer only to voting shares and not to non-voting preference shares.
Executive Board of Sartorius AG

Joachim Kreuzburg, CEO, and interim CFO

Joined Sartorius in 1999
Member of the Board since 2002
Group Strategy, Corp Research, HR, Legal & Compliance, Communications, Sustainability
Responsibilities as interim CFO:
Finance, IT, Data Management, Corp Sourcing

René Fáber

Joined Sartorius in 2002
Member of the Board since 2019
Bioprocess Solutions Division

Alexandra Gatzemeyer

Joined Sartorius in 2005
Member of the Board since May 1, 2023
Lab Products & Services Division

1 Florian Funck was appointed as CFO and member of the Sartorius Executive Board, effective April 1, 2024. Until Funck takes over, Joachim Kreuzburg will assume these responsibilities on an interim basis.
Two-tier Board system of Sartorius AG – Supervisory Board and its committees

- Twelve members, half of the members are shareholders’ representatives and half are employees’ representatives

<table>
<thead>
<tr>
<th>Executive Task Committee</th>
<th>Nomination Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Lothar Kappich (Chairman)</td>
<td></td>
</tr>
<tr>
<td>Annette Becker</td>
<td></td>
</tr>
<tr>
<td>Prof. Dr. Klaus Rüdiger Trützschler</td>
<td></td>
</tr>
<tr>
<td>Manfred Zaffke</td>
<td></td>
</tr>
<tr>
<td>Dr. Daniela Favoccia</td>
<td></td>
</tr>
<tr>
<td>Dr. Lothar Kappich</td>
<td></td>
</tr>
<tr>
<td>Prof. Dr. Klaus Rüdiger Trützschler</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Audit Committee</th>
<th>Conciliation Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof. Dr. Klaus Rüdiger Trützschler (Chairman)</td>
<td></td>
</tr>
<tr>
<td>Dietmar Müller</td>
<td></td>
</tr>
<tr>
<td>Dr. Lothar Kappich</td>
<td></td>
</tr>
<tr>
<td>Manfred Zaffke</td>
<td></td>
</tr>
<tr>
<td>Dr. Lothar Kappich (Chairman)</td>
<td></td>
</tr>
<tr>
<td>Annette Becker</td>
<td></td>
</tr>
<tr>
<td>Prof. Dr. Klaus Rüdiger Trützschler</td>
<td></td>
</tr>
<tr>
<td>Manfred Zaffke</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Position</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>Dr. Joachim Kreuzburg</td>
<td>Chairman</td>
</tr>
<tr>
<td>Dr. René Fáber</td>
<td>CEO</td>
</tr>
<tr>
<td>Romaine Fernandes</td>
<td>Employee representative</td>
</tr>
<tr>
<td>Pascale Boissel</td>
<td></td>
</tr>
<tr>
<td>Susan Dexter</td>
<td></td>
</tr>
<tr>
<td>Anne-Marie Graffin</td>
<td>Lead Independent Director</td>
</tr>
<tr>
<td>Lothar Kappich</td>
<td></td>
</tr>
<tr>
<td>Henri Riey</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Committee</th>
<th>Stakeholders</th>
<th>Independence Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>Audit Committee</td>
<td>• • • • •</td>
<td>43%</td>
</tr>
<tr>
<td>Remuneration &amp; Nomination Committee</td>
<td>• • • • •</td>
<td>75%</td>
</tr>
<tr>
<td>Independence</td>
<td>• • •</td>
<td>75%</td>
</tr>
</tbody>
</table>
ESG aspects included in Sartorius AG executive remuneration

<table>
<thead>
<tr>
<th>Remuneration components</th>
<th>Structure of the remuneration components</th>
<th>Maximum bonus (in % of the target amount)</th>
<th>Maximum remuneration</th>
<th>Further benefits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed remuneration</td>
<td>Basic remuneration + Fringe benefits</td>
<td>100%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Basic amount</td>
<td>100%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Additional amount (matching contribution)</td>
<td>120%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retirement benefits</td>
<td>Sales revenue</td>
<td>Order intake</td>
<td>40%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Group and/or division)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short-term variable remuneration</td>
<td>Underlying EBITDA (Group and/or division)</td>
<td>40%</td>
<td></td>
<td>Clawback</td>
</tr>
<tr>
<td></td>
<td>Ratio of net debt to underlying EBITDA (Group and/or division)</td>
<td>10%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Employee Net Promotor Score (Group and/or division)</td>
<td>10%</td>
<td></td>
<td>Severance cap in the event of early contract termination</td>
</tr>
<tr>
<td>Long-term variable remuneration</td>
<td>Consolidated net profit</td>
<td>25%</td>
<td>120%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reduction of CO₂-equivalent emission intensity</td>
<td>25%</td>
<td>120%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phantom stock units</td>
<td>50%</td>
<td>250%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Share-based payment</td>
<td>One-time allotment; afterwards, no measurement of inflow</td>
<td>Maximum amount of all cash remuneration components for the respective fiscal year</td>
<td>Extraordinary performance</td>
</tr>
</tbody>
</table>
Corporate responsibility & further financial information

To Sartorius, sustainability means operating responsibly over the long term – with respect to business partners, employees and society as well as to natural resources. Learn more about our commitment:

- SRI Presentation
- Sustainability Report 2022

Please click below for further financial information:

- Earnings Release FY 2023
- Annual Report 2023
- Non-financial Group Statement 2023
- Corporate Governance Report 2023
- Earnings Release 9M 2023
- Half Year Report H1 2023
Contacts and Financial calendar

- **March 12-13, 2024**
  Barclays Global Healthcare Conference | Miami

- **March 20, 2024**
  KeyBanc Life Sciences & Medtech Investor Forum | Virtual

- **March 28, 2024**
  Annual Shareholders’ Meeting | Virtual

- **April 28, 2024**
  Publication Q1 2024 Results

- **May 16, 2024**
  Capital Markets Day | Goettingen

- **Jul 19, 2024**
  Publication Half-Year Report 2024

- **Oct 17, 2024**
  Publication 9M 2024 Results

Petra Kirchhoff
Head of Corporate Communications & IR
+49.551.308.1686
petra.kirchhoff@sartorius.com

Petra Müller
Head of Investor Relations
+49.551.308.6035
petra.mueller2@sartorius.com

Mirko Koch
Manager Investor Relations
+49.551.308.2402
mirko.koch@sartorius.com

Sartorius Corporate Administration GmbH
Otto-Brenner-Straße 20
37079 Göttingen, Germany
Disclaimer

This presentation contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.

Throughout this presentation, differences may be apparent as a result of rounding during addition.